• CRMD

Earnings call: CorMedix Inc. reports Q3 financials, DefenCath drives growth

CorMedix Inc. reported $11.5M net revenue in Q3 2024, driven by DefenCath sales, anticipates positive EBITDA in Q4, despite a $2.8M net loss.